How the 2026 U.S. tariff action on branded drugs reshapes global pharma—and what it really means for Indian generics
Executive Summary
In April 2026, Donald Trump announced tariffs of up to 100% on imported patented (branded) pharmaceuticals, targeting companies that do not align with U.S. pricing expectations or expand domestic manufacturing. Crucially, generic medicines are exempt. For India—one of the largest suppliers of generics to the United States—this creates a paradox:
Free Membership Required
You must be a Free member to access this content.
Already a member? Log in here
